Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

Koji Sasaki, Hagop M. Kantarjian, Preetesh Jain, Elias J. Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Koichi Takahashi, Naveen Pemmaraju, Naval Daver, Sherry A. Pierce, Susan M. O'Brien, Jorge E. Cortes

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

BACKGROUND Tyrosine kinase inhibitors (TKIs) significantly improve survival in patients with chronic myeloid leukemia in chronic phase (CML-CP). Conditional probability provides survival information in patients who have already survived for a specific period of time after treatment. METHODS Cumulative response and survival data from 6 consecutive frontline TKI clinical trials were analyzed. Conditional probability was calculated for failure-free survival (FFS), transformation-free survival (TFS), event-free survival (EFS), and overall survival (OS) according to depth of response within 1 year of the initiation of TKIs, including complete cytogenetic response, major molecular response, and molecular response with a 4-log or 4.5-log reduction. RESULTS A total of 483 patients with a median follow-up of 99.4 months from the initiation of treatment with TKIs were analyzed. Conditional probabilities of FFS, TFS, EFS, and OS for 1 additional year for patients alive after 12 months of therapy ranged from 92.0% to 99.1%, 98.5% to 100%, 96.2% to 99.6%, and 96.8% to 99.7%, respectively. Conditional FFS for 1 additional year did not improve with a deeper response each year. Conditional probabilities of TFS, EFS, and OS for 1 additional year were maintained at >95% during the period. CONCLUSIONS In the era of TKIs, patients with chronic myeloid leukemia in chronic phase who survived for a certain number of years maintained excellent clinical outcomes in each age group.

Original languageEnglish (US)
Pages (from-to)238-248
Number of pages11
JournalCancer
Volume122
Issue number2
DOIs
StatePublished - Jan 15 2016

Keywords

  • chronic myeloid leukemia
  • conditional survival
  • response
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors'. Together they form a unique fingerprint.

  • Cite this

    Sasaki, K., Kantarjian, H. M., Jain, P., Jabbour, E. J., Ravandi, F., Konopleva, M., Borthakur, G., Takahashi, K., Pemmaraju, N., Daver, N., Pierce, S. A., O'Brien, S. M., & Cortes, J. E. (2016). Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer, 122(2), 238-248. https://doi.org/10.1002/cncr.29745